Quarter-Dose (0.025 mmol/kg) Gadobenate Dimeglumine for Abdominal MRI in Patients at Risk for Nephrogenic Systemic Fibrosis: Preliminary Observations

Nephrogenic Systemic Fibrosis: A Survey of Nephrologists' Perceptions and Practices

(2010) K. Abdel-Kader et al.   Clinical Journal of the American Society of Nephrology

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols

(2010) Diego R. Martin et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Nephrogenic Systemic Fibrosis and Management of High-risk Patients

(2009) Ersan Altun et al.   ACADEMIC RADIOLOGY

Frequency and Severity of Adverse Effects of Iodinated and Gadolinium Contrast Materials: Retrospective Review of 456,930 Doses

(2009) Christopher H. Hunt et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI

(2009) B.J. Bryant et al.   CLINICAL RADIOLOGY

Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients

(2009) Hani H. Abujudeh et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Quantitative and qualitative comparison of 1.5 and 3.0 tesla MRI in patients with chronic liver diseases

(2009) Miguel Ramalho et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Enhancement of abdominal organs on hepatic arterial phase: quantitative comparison between 1.5- and 3.0-T magnetic resonance imaging

(2009) Jose A. Goncalves Neto et al.   MAGNETIC RESONANCE IMAGING

Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging

(2009) Martin R. Prince et al.   RADIOGRAPHICS

Use of 3.0-T MR Imaging for Evaluation of the Abdomen

(2009) Sukru Mehmet Erturk et al.   RADIOGRAPHICS

How to Avoid Nephrogenic Systemic Fibrosis: Current Guidelines in Europe and the United States

(2009) Henrik S. Thomsen   RADIOLOGIC CLINICS OF NORTH AMERICA

Nephrogenic Systemic Fibrosis: Change in Incidence Following a Switch in Gadolinium Agents and Adoption of a Gadolinium Policy—Report from Two U.S. Universities

(2009) Ersan Altun et al.   RADIOLOGY

Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment—Report of 33 Cases

(2009) Javier Perez-Rodriguez et al.   RADIOLOGY

Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients

(2009) Hani H. Abujudeh et al.   RADIOLOGY

Quality Initiatives MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient Safety

(2008) Krishna Juluru et al.   RADIOGRAPHICS

Nephrogenic Systemic Fibrosis: A Chemical Perspective

(2008) Neil M. Rofsky et al.   RADIOLOGY

Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities

(2008) Rebecca Wertman et al.   RADIOLOGY

Focal liver lesions: Whether a standard dose (0.05mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1mmol/kg dose

(2007) Mehmet Selim Nural et al.   EUROPEAN JOURNAL OF RADIOLOGY